Related Experiment Video
Updated: Oct 17, 2026

Catheter-based Endovascular Angioplasty for Fibrosing Mediastinitis-associated Pulmonary Vein Stenosis
Published on: August 26, 2025
[Chronic pulmonary heart diseases treated by fraxiparin]
1Department of Internal Medicine, Second Affiliated Hospital, Hunan Medical University, Changsha.
Objective:
The effects of fraxiparine with hypodermic on the treatment of patients with chronic pulmonary heart diseases(CPHD) at acute phase were studied.
Methods:
Twenty patients were hypodermically injected with 0.4 ml fraxiparine per day for 7 days as a course. Fibrin fibrinogen degradation products (FDP and D-dimer), antithrombin III (AT-III), PaO2 and PaCO2 were detected before and after the treatment.
Results:
In the therapy group, FDP and D-dimer decreased after the treatment, AT-III increased. All indexes didn't alter in the control group.
Conclusion:
Fraxiparine is effective on patients with CPHD at acute phase.
Related Concept Videos
Peripheral Artery Disease III: Interprofessional Care
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
Venous Thrombosis III: Interprofessional Care
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Heart Failure V: Medical Management